Company intelligence / Profile preview

DiaCarta

Pleasanton, California, United Statesdiacarta.com ↗

Ownership: Private
Employees: ~53
Development stage: Commercial

Overview

DiaCarta has commercialized several precision diagnostic products for early cancer detection and therapy monitoring. Its ColoScape™ test enables early colorectal cancer detection from blood samples with high sensitivity using proprietary XNA-qPCR technology. The company’s RadTox™ cfDNA test personalizes radiation/chemotherapy by assessing tumor response via liquid biopsy. Their QuantiVirus™ SARS-CoV‑2 test received FDA EUA approval during the pandemic [1][3][5]. No clinical trial results are reported as they are not a therapeutics company.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Molecular diagnosticsLiquid biopsy technology
Industry: Molecular Diagnostics

Partnerships

Capstone Health AllianceHH&L Acquisition Co.

Beyond the preview

Go deeper on DiaCarta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DiaCarta.

Explore the full profile